[Ip-health] Reuters: Pricing, lack of tools hamper child AIDS treatment

[Sheila.SHETTLE@geneva.msf.org]

Pricing, lack of tools hamper child AIDS treatment
Tue Aug 15, 2006 2:02 PM ET



By Cameron French


TORONTO (Reuters) - Doctors trying to treat HIV-infected newborns in
sub-Saharan Africa are being held back by over-priced treatments, an
absence of diagnostic tools, and a general lack of focus from policymakers
and international organizations, Medecins Sans Frontieres said on Tuesday.


Most of the 2.3 million children infected with the virus live in southern
Africa but the pharmaceutical industry is based largely in richer western
countries, where many fewer children are infected, the group said in a
report released at the 16th International AIDS conference in Toronto.


The group, also known as Doctors Without Borders, said that only five
percent of the 660,000 young children in urgent need of treatment were
actually receiving it. Unfortunately, they added, the treatment was hard to
come by, and what was available was over priced.


"We want to do more. We know what we're doing is not enough, because our
hands are tied," Moses Masaquoi, an MSF doctor working in Malawi, told a
news conference.


Masaquoi said a lack of pediatric formulations of HIV drugs meant that
doctors were forced to split adult tablets that were not meant to be taken
in parts, while the small amount of child-designed treatment that was
available is difficult to store and administer as it needed refrigeration,
which could be tough in hot, poorer countries.


Pricing discrepancies also hamper their efforts, as the few companies that
produce child dosages price them higher than adult dosages, even though
they carry about one-fifth of the active ingredient of the adult dosages.


"Prices of pediatric formulas are not justified," Fernando Pascual, a
pharmacist with MSF, told the news conference.


The group is calling on policymakers and groups such as the World Health
Organization and UNICEF to give clear guidance to drug manufacturers to
produce child-specific formulations, and says national governments need to
take the issue more seriously.


Nine out of 10 newly infected children acquire the virus through
mother-to-child transmission, but diagnostic tests generally used for
adults are not always accurate for infants.


Compounding the problem is the fact that most pregnant mothers do not have
access to prenatal care, the group said.


This has created a large treatment gap for children in the region, and has
frustrated doctors who have seen noticeable results when children have
received treatment.


MSF studies show that of children that did receive early treatment, 80
percent were alive after 2 years, while half of children who acquired the
virus through mother-to-child transmission died before the age of two.


Also speaking at the AIDS conference on Tuesday, former U.S. President Bill
Clinton said the price of pediatric HIV drug formulations had, over the
past four years, been bargained down from $600 a year to $200 a year.


+++++++++++++++++++++
at Toronto AIDS Conference:  +1.416.455.7916
+++++++++++++++++++++
Sheila Shettle
Communications Officer
M=E9decins Sans Fronti=E8res
Campaign for Access to Essential Medicines
Rue de Lausanne 78
1211 Geneva
Switzerland
+ 41.22.849.8403
sheila.shettle@geneva.msf.org
www.accessmed-msf.org